Quick Answer
Roivant Sciences Ltd. reported Total Revenue of $29.05 million for the year ending 2025.
- Roivant Sciences Ltd. showed a decrease of -11.2% in Total Revenue from 2024 to 2025.
- This data is from Roivant Sciences Ltd.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.58 million | Q3 2020: $1.32 million | Q4 2020: $5.75 million | Q2 2021: $7.74 million | Q3 2021: $13.99 million | Q4 2021: $24.34 million | Q2 2022: $4.32 million | Q3 2022: $12.53 million | Q4 2022: $17.05 million | Q2 2023: $21.62 million | Q3 2023: $3.65 million | Q4 2023: $15.56 million | Q2 2024: $7.99 million | Q3 2024: $4.48 million | Q4 2024: $9.02 million | Q2 2025: $2.17 million | Q3 2025: $1.57 million | Q4 2025: $2.00 million.
- Over the full 5 years of available data (2021 to 2025), Roivant Sciences Ltd.'s Total Revenue has grown by 22.1%.
- Historical annual values: Fiscal year 2025: $29.05 million | Fiscal year 2024: $32.71 million | Fiscal year 2023: $31.53 million | Fiscal year 2022: $55.29 million | Fiscal year 2021: $23.80 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: